Dragonfly Therapeutics

Dragonfly Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, founded in 2016 by Tyler Jacks, Bill Haney and David Raulet to develop natural killer (NK) cell-based immunotherapies. Its proprietary TriNKET (Tri-specific NK cell Engager Therapy) and cytokine engager platforms produce molecules that bind both a tumor or disease antigen and an NK cell activating receptor, recruiting innate and adaptive immunity against cancer, autoimmune disease, fibrosis and neuro-inflammation. Lead clinical candidate DF1001 targets HER2 in advanced solid tumors, and the platform is licensed under multi-target collaborations with AbbVie, Bristol Myers Squibb, Merck and Gilead. Dragonfly is a therapeutics developer rather than a software company: it publishes no developer program, no public API, no SDKs and no machine-readable API contract. The only agent-readable surfaces on its own host are the llms.txt and Model Context Protocol endpoint automatically provisioned by its Wix website platform.

Dragonfly Therapeutics publishes 1 API on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunotherapy, and Oncology.

Dragonfly Therapeutics’ developer surface includes engineering blog, product news, authentication, and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub
16.8/100 emerging ▬ flat Agent 23/100 agent aware Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
1 APIs 1 MCP Servers
CompanyBiotechnologyPharmaceuticalsImmunotherapyOncologyLife SciencesClinical StageDrug DiscoveryHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 16.8/100 · emerging
Contract Quality 0.0 / 21
Developer Ergonomics 3.7 / 17
Commercial Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Governance 1.3 / 10
Discoverability 6.1 / 9
Regulatory Posture 3.9 / 15
Agent readiness — 23/100 · agent aware
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 12 / 12
Machine-Readable Auth 10 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 7 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dragonfly-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

APIs 1

Individual APIs this provider publishes, each with its own machine-readable definition.

Dragonfly Therapeutics Site MCP

Model Context Protocol endpoint served from the Dragonfly Therapeutics website host. This is a platform-provided surface automatically provisioned by Wix for every site it build...

MCP Servers 1

Model Context Protocol servers that expose these APIs to AI agents.

dragonfly-therapeutics-mcp.yml

MCP SERVER

Pricing Plans 1

Published pricing tiers and plan structures.

Dragonfly Therapeutics Plans Pricing

0 plans

PLANS

Rate Limits 1

Documented rate limits and quota policies.

Dragonfly Therapeutics Rate Limits

0 limits

RATE LIMITS

Security Posture 2

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Dragonfly Therapeutics Authentication

none/bearer-visitor-token · 2 schemes

SECURITY

Dragonfly Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt
 MCPServer
MCPServer

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance
Conformance

Access & Security 2

Authentication, authorization, and security posture

Authentication
Authentication
 DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 5

The organization behind the API

Website
Website
 Blog
Blog
 BlogRSS
BlogRSS
 News
News
 LinkedIn
LinkedIn

Other 1

Properties that don't map to a standard resource type

Profile
Profile

Source (apis.yml)

apis.yml Raw ↑ 
aid: dragonfly-therapeutics
name: Dragonfly Therapeutics
description: 'Dragonfly Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, founded in
  2016 by Tyler Jacks, Bill Haney and David Raulet to develop natural killer (NK) cell-based immunotherapies. Its proprietary
  TriNKET (Tri-specific NK cell Engager Therapy) and cytokine engager platforms produce molecules that bind both a tumor or
  disease antigen and an NK cell activating receptor, recruiting innate and adaptive immunity against cancer, autoimmune disease,
  fibrosis and neuro-inflammation. Lead clinical candidate DF1001 targets HER2 in advanced solid tumors, and the platform
  is licensed under multi-target collaborations with AbbVie, Bristol Myers Squibb, Merck and Gilead. Dragonfly is a therapeutics
  developer rather than a software company: it publishes no developer program, no public API, no SDKs and no machine-readable
  API contract. The only agent-readable surfaces on its own host are the llms.txt and Model Context Protocol endpoint automatically
  provisioned by its Wix website platform.'
url: https://raw.githubusercontent.com/api-evangelist/dragonfly-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunotherapy
- Oncology
- Life Sciences
- Clinical Stage
- Drug Discovery
- Healthcare
apis:
- name: Dragonfly Therapeutics Site MCP
  description: 'Model Context Protocol endpoint served from the Dragonfly Therapeutics website host. This is a platform-provided
    surface automatically provisioned by Wix for every site it builds — not a first-party Dragonfly Therapeutics product API.
    It answers an unauthenticated JSON-RPC 2.0 tools/list with nine tools that let an agent read business details, search
    site content, obtain a visitor token and call Wix site APIs on a visitor''s behalf. Verified live on 2026-08-12: tools/list
    returned HTTP 200 with real inputSchema per tool, and a GetBusinessDetails call returned the site''s business record.'
  humanURL: https://www.dragonflytx.com/
  baseURL: https://www.dragonflytx.com/_api/mcp
  tags:
  - MCP
  - Agent
  - Website
  properties:
  - type: MCPServer
    url: mcp/dragonfly-therapeutics-mcp.yml
  - type: Authentication
    url: authentication/dragonfly-therapeutics-authentication.yml
  - type: RateLimits
    url: rate-limits/dragonfly-therapeutics-rate-limits.yml
  - type: Plans
    url: plans/dragonfly-therapeutics-plans-pricing.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.dragonflytx.com/
- type: Blog
  url: https://www.dragonflytx.com/blog
- type: BlogRSS
  url: https://www.dragonflytx.com/blog-feed.xml
- type: News
  url: https://www.dragonflytx.com/news
- type: PrivacyPolicy
  url: https://www.dragonflytx.com/_files/ugd/cb0357_e5861f3f611f4e3091162162753c2083.pdf
- type: LinkedIn
  url: https://www.linkedin.com/company/dragonfly-therapeutics-inc.
- type: Profile
  name: Hiive secondary-market listing
  url: https://www.hiive.com/securities/dragonfly-therapeutics-stock
- type: LLMsTxt
  url: llms/dragonfly-therapeutics-llms.txt
- type: MCPServer
  url: mcp/dragonfly-therapeutics-mcp.yml
- type: Authentication
  url: authentication/dragonfly-therapeutics-authentication.yml
- type: Conformance
  url: conformance/dragonfly-therapeutics-conformance.yml
- type: DomainSecurity
  url: security/dragonfly-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 9
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Dragonfly Therapeutics is a clinical-stage NK-cell immunotherapy developer whose product is a drug pipeline, not
    software; the whole site is ten Wix pages with no developer, API or docs route, and the only machine-readable surfaces
    (llms.txt and a /_api/mcp endpoint) are boilerplate auto-provisioned by Wix rather than anything the company authored.
  evidence:
  - url: https://www.dragonflytx.com/developers
    status: 404
  - url: https://www.dragonflytx.com/api-docs
    status: 404
  - url: https://www.dragonflytx.com/openapi.json
    status: 400
  - url: https://www.dragonflytx.com/.well-known/agent-card.json
    status: 400
  - url: https://www.dragonflytx.com/llms.txt
    status: 200
  - url: https://www.dragonflytx.com/_api/mcp
    status: 200
  checked: '2026-08-12'